The findings of a phase III trial comparing the efficacy of the second-generation tyrosine-kinase inhibitor (TKI) dacomitinib with that of the first-generation TKI gefitinib in patients with newly diagnosed non-small-cell lung cancer reveal superior progression-free survival in the dacomitinib group (14.7 versus 9.2 months; P <0.0001). However, dacomitinib also substantially increased the risk of grade ≥3 adverse events (in 51% versus 30% of patients), including two treatment-related deaths in the dacomitinib group versus one in the gefitinib group.
References
Wu, Y. L. et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(17)30608-3 (2017)
Rights and permissions
About this article
Cite this article
Sidaway, P. Dacomitinib delays disease progression. Nat Rev Clin Oncol 14, 712 (2017). https://doi.org/10.1038/nrclinonc.2017.162
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.162